| |
Efficacy and safety of long-acting cabotegravir
and rilpivirine in adults with adherence or engagement
challenges in sub-Saharan Africa: the IMPALA trial 96-week results
|
| |
| |
IAS 2026 Rio Brazil July 26-31
IAS2025: Long-acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub-Saharan Africa:
the IMPALA trial 48-week results ......https://www.natap.org/2025/IAS/IAS_29.htm
|
|
| |
| |
|
|
|
